MavriX Bio reports first patient dosed in Phase 1/2 trial of MVX-220 for AS

Johnson & Johnson's DARZALEX FASPRO receives US FDA approval

Calico Life Sciences' ABBV-CLS-628S granted US FDA Orphan Drug Designation

Lunai Bioworks publishes breakthrough on second-generation allogeneic dendritic cell therapy in vaccines

Oxford Nanopore and bioMérieux introduce AmPORE-TB for rapid tuberculosis resistance characterisation

Cizzle Biotechnology signs Letter of Intent with UK diagnostic provider

HUTCHMED completes enrollment of global Phase III SAFFRON trial for ORPATHYS and TAGRISSO combination in lung cancer

Spinogenix reveals positive SPG302 topline results from Phase 2a study for treatment of ALS

iLeukon reports FDA clearance of IND application for phase II study of ILKN421H in advanced NSCLC

AVEO Oncology signs development and option agreement with HiberCell

Merck assumes full development rights for investigational antibody MK-8690

Merck secures USD700m R&D funding from Blackstone Life Sciences for cancer drug sacituzumab tirumotecan

Arctic Bioscience reports significant anti-inflammatory effects from psoriasis drug candidate HRO350 in phase 2b trial

UCB's KYGEVVI receives FDA approval for TK2d treatment

Camurus launches Oczyesa in Germany for patients with acromegaly